Posts by Muana Minkoué
Actival and Neuria receive CHF 40’000 from Venture Kick
Actival and Neuria Digital Therapeutics were selected at Venture Kick’s second financial and entrepreneurial support stage. Actival: 3D printing a novel generation of active dental aligners Clear dental aligners have recently caused one of the biggest disruptions in the dental industry. They are a transparent and removable alternative to traditional metal braces and…
Read MoreFour Swiss Health Valley biotech companies worth keeping an eye out for in 2024
Labiotech.eu, a leading digital media covering the European Biotech industry, published a list of Swiss biotech companies to put on your radar. Switzerland is home to a thriving biotech industry, with strong research institutions many companies leading the way in cutting-edge research for new cancer treatments and immunotherapies, from startups to multinationals. Labiotech highlighted…
Read MoreThe Patient Quality of Life Challenge announced its finalists
Supported by Debiopharm, La-Solution.ch and the Inartis Foundation, the aim of this award is to support a selection of projects over a 4-month period to enable prototypes to be developed and produced. At the end of the year, the winner (or co-winners) whose prototype is judged to be the best will receive a prize of…
Read MoreAktiia receives regulatory approval
Aktiia, the Swiss startup revolutionizing Blood Pressure (BP) monitoring and management, announces it has received regulatory approval (CE mark) for its next-generation optical technology that does not require calibration with a traditional cuff. The CE mark allows market access to potentially over 40 countries. The underlying groundbreaking calibration-free technology, known as CALFREE™, uses…
Read MoreINCAPTEK wins Exhibitors’ Grand Prix at EPHJ
The 2024 Exhibitors’ Grand Prix was awarded to Incaptek, a Jura-based company, for its cutting-edge new technology for producing ultra-resistant composite materials. EPHJ, the international high-precision trade show, closed the doors of its 22nd edition with record attendance and a quality of Swiss and international trade visitors praised by the 765 exhibitors. During…
Read MoreWyss Center reported a new breakthrough in brain monitoring
Research teams at the Wyss Center in partnership with, Inselspital unveiled a groundbreaking long-term EEG system that facilitates continuous monitoring of brain activity in real-life settings. This innovative technology has the potential to revolutionise epilepsy treatment and advance understanding of various neurological disorders. Current practice in clinical neurophysiology is limited to short recordings…
Read MoreOculis just announced positive topline results of phase 2b RELIEF Trial
Oculis, announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED). The Phase 2b RELIEF trial is a multi-centre, randomised, double-masked, vehicle-controlled trial evaluating the efficacy and safety…
Read MoreLimula raises CHF 6.2 Million
Limula raises CHF 6.2 Million in oversubscribed Seed round to develop automated Cell and Gene Therapy manufacturing platform. The oversubscribed seed round was led by LifeX Ventures, with participation from the founders, Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, W.A. de Vigier Foundation, and a line-up of private individuals who have…
Read MoreMyota publishes new clinical trial results in pre-diabetes
Myota is thrilled to announce that their results have been published in the prestigious British Journal of Nutrition, and the results are nothing short of groundbreaking. In this study, Myota showed that pre-diabetic patients given Myota fibres showed significant improvements in insulin sensitivity, systemic inflammation, and HbA1c in individuals earlier on in the…
Read MoreOrio Therapeutics receives CHF 150’000 from Venture Kick
Orio Therapeutics obtains the CHF 150,000 Kick to redefine regenerative medicine through protein engineering. Orio Therapeutics modifies therapeutic proteins using a patented technology. This modification improves drug delivery by controlling the localisation of the protein after injection. Its approach ensures enhanced efficacy and reduced dosage, addressing the limitations of uncontrolled drug delivery in…
Read More